Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.01 AUD | -0.60% | -2.91% | -18.54% |
04:11am | Swissmedic Grants Mayne Pharma Group Expanded Kapanol Dosage Approvals in Switzerland | MT |
May. 24 | Mayne Pharma Reiterates H2 FY24 Outlook in Wake of Change Healthcare Cyberattack | MT |
Sales 2024 * | 383M 254M | Sales 2025 * | 426M 283M | Capitalization | 409M 272M |
---|---|---|---|---|---|
Net income 2024 * | -88M -58.45M | Net income 2025 * | -19M -12.62M | EV / Sales 2024 * | 0.86 x |
Net cash position 2024 * | 79.89M 53.07M | Net cash position 2025 * | 53.05M 35.24M | EV / Sales 2025 * | 0.84 x |
P/E ratio 2024 * |
-4.65
x | P/E ratio 2025 * |
-20.7
x | Employees | 967 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.67% |
Latest transcript on Mayne Pharma Group Limited
1 day | -0.60% | ||
1 week | -2.91% | ||
Current month | -0.60% | ||
1 month | -32.02% | ||
3 months | -26.43% | ||
6 months | -7.73% | ||
Current year | -18.54% |
Managers | Title | Age | Since |
---|---|---|---|
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
Aaron Gray
DFI | Director of Finance/CFO | - | 22-08-28 |
Keith Moore
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Frank Condella
CHM | Chairman | 70 | 18-05-29 |
Patrick Blake
BRD | Director/Board Member | 59 | 18-06-27 |
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 5.01 | -0.60% | 168 919 |
24-05-31 | 5.04 | +0.40% | 205,122 |
24-05-30 | 5.02 | +0.80% | 146,364 |
24-05-29 | 4.98 | -2.54% | 259,013 |
24-05-28 | 5.11 | -0.97% | 571,845 |
Delayed Quote Australian S.E., June 03, 2024 at 02:10 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.54% | 272M | |
+15.61% | 41.97B | |
+22.56% | 22.34B | |
+18.48% | 15.25B | |
+16.34% | 14B | |
+49.23% | 12.06B | |
-10.77% | 6.8B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+14.18% | 5.49B |
- Stock Market
- Equities
- MYX Stock